- ISIN
- US0070021086
- CUSIP
- 007002108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 26, 2018
Highlights
- Market Cap
- $88.43M
- Enterprise Value
- $68.96M
- EPS (TTM)
- -$15.00
- Gross Profit (TTM)
- -$1.47M
- EBITDA (TTM)
- -$110.77M
- Year Range
- $6.01 - $17.44
- Target Price
- $18.00
- ROA (TTM)
- -64.25%
- ROE (TTM)
- -77.70%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ACET Performance Chart
Adicet Bio, Inc. (ACET) is down 2.3% since the beginning of the year. At $8 per share, ACET is trading 52.8% below its 52-week high of $17. Investors who bought $1,000 worth of ACET shares 5 years ago would now be looking at an investment worth $56.
Loading charts...
Returns By Period
Adicet Bio, Inc. (ACET) has returned -2.26% so far this year and -23.23% over the past 12 months.
Adicet Bio, Inc.
- 1D
- 1.60%
- 1M
- -0.84%
- YTD
- -2.26%
- 6M
- 4.59%
- 1Y
- -23.23%
- 3Y*
- -52.27%
- 5Y*
- -43.82%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ACET Monthly Returns History
Based on dividend-adjusted daily data since Jan 26, 2018, ACET's average daily return is -0.05%, while the average monthly return is -1.66%.
Historically, 41% of months were positive and 59% were negative. The best month was Jul 2018 with a return of +68.2%, while the worst month was Nov 2019 at -83.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, ACET closed higher 47% of trading days. The best single day was Jul 25, 2018 with a return of +49.5%, while the worst single day was Nov 15, 2019 at -86.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.11% | -9.26% | -6.07% | 10.87% | 23.31% | -11.60% | -2.26% | ||||||
| 2025 | -8.00% | 1.56% | -16.00% | -12.30% | 8.49% | -15.08% | 12.39% | 5.02% | 12.53% | -7.43% | -13.57% | -18.81% | -45.30% |
| 2024 | 58.20% | -21.40% | 0.00% | -36.60% | -2.68% | -16.55% | 24.79% | -3.31% | -1.37% | -11.11% | -11.72% | -14.87% | -49.10% |
| 2023 | 2.35% | -13.88% | -26.90% | 1.39% | -6.16% | -55.66% | 9.88% | -25.09% | -31.50% | -3.65% | -10.61% | 60.17% | -78.86% |
| 2022 | -27.84% | 3.65% | 52.68% | -26.19% | -19.81% | 23.52% | 15.68% | -16.16% | 0.42% | 15.96% | 10.25% | -50.83% | -48.89% |
| 2021 | -12.46% | 24.47% | -14.57% | 21.79% | -15.76% | -23.32% | -28.09% | 12.84% | -6.11% | 9.69% | 23.72% | 64.38% | 24.48% |
Benchmark Metrics
Adicet Bio, Inc. has an annualized alpha of -24.42%, beta of 1.14, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since January 26, 2018.
- This stock participated in 219.27% of S&P 500 Index downside but only 15.97% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -24.42%
- Beta
- 1.14
- R²
- 0.06
- Upside Capture
- 15.97%
- Downside Capture
- 219.27%
Return for Risk
Risk / Return Rank
ACET ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Adicet Bio, Inc. (ACET) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACET | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.34 | ||
| Sortino ratioReturn per unit of downside risk | -2.73 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | -0.37 | 2.78 | -3.15 |
| Martin ratioReturn relative to average drawdown | -0.56 | 12.44 | -13.00 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Adicet Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Adicet Bio, Inc. was 99.74%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Adicet Bio, Inc. drawdown is 99.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.74%Mar 2026 | 8y 1mo | — | 8y 3moFeb 2018 - now |
2018 correction2018 | -15.47%Jan 2018 | 4d | 17d | 21dJan 2018 - Feb 2018 |
2018 pullback2018 | -0.20%Feb 2018 | 0s | 1d | 1dFeb 2018 - Feb 2018 |
Drawdown Indicators
| ACET | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.74% | -56.78% | -42.96% |
Max Drawdown (1Y)Largest decline over 1 year | -63.28% | -9.10% | -54.18% |
Max Drawdown (3Y)Largest decline over 3 years | -91.93% | -18.90% | -73.03% |
Max Drawdown (5Y)Largest decline over 5 years | -98.20% | -25.43% | -72.77% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.65% | -1.80% | -97.85% |
Average DrawdownAverage peak-to-trough decline | -85.41% | -10.71% | -74.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.80% | 2.03% | +39.77% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Adicet Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Adicet Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ACET in comparison with other companies in the Biotechnology industry. Currently, ACET has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ACET
Add Adicet Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ACET